Public Profile

Ono Pharmaceutical

Ono Pharmaceutical Co., Ltd., commonly referred to as Ono Pharma, is a prominent player in the biopharmaceutical industry, headquartered in Osaka, Japan. Founded in 1717, the company has a rich history of innovation, focusing on the research, development, and commercialisation of novel therapeutics, particularly in oncology, immunology, and pain management. Ono Pharma is renowned for its flagship product, Opdivo (nivolumab), a groundbreaking immunotherapy that has transformed cancer treatment paradigms. The company’s commitment to advancing healthcare is reflected in its robust pipeline and strategic partnerships, positioning it as a leader in the global pharmaceutical market. With a strong presence in Japan and expanding operations in North America and Europe, Ono Pharmaceutical continues to make significant strides in delivering unique and effective solutions for patients worldwide.

DitchCarbon Score

How does Ono Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

67

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Ono Pharmaceutical's score of 67 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.

99%

Let us know if this data was useful to you

Ono Pharmaceutical's reported carbon emissions

In 2023, Ono Pharmaceutical reported total greenhouse gas emissions of approximately 36,000,000 kg CO2e, comprising 6,700,000 kg CO2e from Scope 1, 9,400,000 kg CO2e from Scope 2, and 23,600,000 kg CO2e from Scope 3 emissions. This represents a significant commitment to reducing their carbon footprint, with a target to achieve carbon neutrality for Scope 1 and 2 emissions by 2025, moving the goal for zero emissions from 2050 to 2035. Ono has set ambitious reduction targets, aiming for a 55% reduction in absolute Scope 1 and 2 emissions by FY2030, and a 30% reduction in Scope 3 emissions by the same year, both from a FY2017 baseline. The company is also committed to achieving zero greenhouse gas emissions by FY2035. These initiatives align with industry standards for climate action, demonstrating Ono Pharmaceutical's dedication to sustainability and responsible environmental stewardship.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20162017201820192020202120222023
Scope 1
-
0,000,000
0,000,000
0,000,000
0,000,000
0,000,000
0,000,000
0,000,000
Scope 2
-
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
0,000,000
Scope 3
-
00,000,000
00,000,000
0,000,000
0,000,000
0,000,000
00,000,000
00,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Ono Pharmaceutical's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Ono Pharmaceutical is in JP, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Ono Pharmaceutical is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Takeda

JP
Pharmaceutical Preparation Manufacturing
Updated 6 days ago

Merck And Co

US
Pharmaceutical Preparation Manufacturing
Updated about 17 hours ago

MERCK Kommanditgesellschaft auf Aktien

DE
Pharmaceutical Preparation Manufacturing
Updated about 3 hours ago

BioMarin

US
Chemicals nec
Updated 13 days ago

Amgen

US
Chemicals nec
Updated 1 day ago

Glaxosmithkline

GB
Pharmaceutical Preparation Manufacturing
Updated 6 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers